biostudies-literaturePreussler JMChildren's Leukemia Research AssociationVidacare CorporationTHERAKOS, Inc.CaridianBCTMerck & CompanyNHLBI NIH HHSPall Life SciencesSchering CorporationViraCor LaboratoriesClinImmune LabsAstellas Pharma US, Inc.Nature Publishing GroupOtsuka America Pharmaceutical, Inc.Miller Pharmacal GroupHistogenetics, Inc.CTI Clinical Trial and Consulting ServicesBe the Match FoundationMilliman USA, Inc.Sigma-Tau PharmaceuticalsBiovitrum ABMedical College of WisconsinPfizer IncViroPharma, Inc.Genentech, Inc.StemCyte, Inc.NCIAmgen, Inc.Osiris Therapeutics, Inc.Miltenyi Biotec, Inc.Bone Marrow FoundationBuchanan Family FoundationEisai, Inc.BioMarin Pharmaceutical, Inc.CellGenix, GmbHNovartis OncologySoligenix, Inc.StemSoft Software, Inc.National Marrow Donor ProgramBloodCenter of WisconsinWellpoint, Inc.National Cancer InstituteCelgene CorporationKirin Brewery Co., Ltd.Health Resources and Services AdministrationOncology Nursing SocietyMillennium Pharmaceuticals, Inc.the National Heart, Lung and Blood InstituteOffice of Naval ResearchNational Institute of Allergy and Infectious DiseasesNHLBISysmex America, Inc.Hospira, Inc.Blue Cross and Blue Shield AssociationPublic Health ServiceNCI NIH HHSBiogen IDECLeukemia & Lymphoma SocietyGenzyme CorporationHKS Medical Information SystemsAABBAllos, Inc.1021-1028https://www.ebi.ac.uk/biostudies/studies/S-EPMC5497312biostudies-literatureUnknown23(6)The primary aim of this study was to describe healthcare costs and utilization during the first year after a diagnosis of acute myeloid leukemia (AML) for privately insured non-Medicare patients in the United States aged 50 to 64 years who were treated with either chemotherapy or chemotherapy and allogeneic hematopoietic cell transplantation (alloHCT). MarketScan (Truven Health Analytics) adjudicated total payments for inpatient, outpatient, and prescription drug claims from 2007 to 2011 were used to estimate costs from the health system perspective. Stabilized inverse propensity score weights were constructed using logistic regression to account for differential selection of alloHCT over chemotherapy. Weighted generalized linear models adjusted costs and utilization (hospitalizations, inpBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHealthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.PMC54973125U01HL069294N00014-06-1-0704U24-CA76518U24 CA076518HHSH234200637018CN00014-08-1-0058U01 HL069294HHSH234200637015CDenzen EMPreussler JMMeyer CLEdsall KCSaber WVanness DJMajhail NSMau LWBurns LJFarnia SHfalseHealthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.The primary aim of this study was to describe healthcare costs and utilization during the first year after a diagnosis of acute myeloid leukemia (AML) for privately insured non-Medicare patients in the United States aged 50 to 64 years who were treated with either chemotherapy or chemotherapy and allogeneic hematopoietic cell transplantation (alloHCT). MarketScan (Truven Health Analytics) adjudicated total payments for inpatient, outpatient, and prescription drug claims from 2007 to 2011 were used to estimate costs from the health system perspective. Stabilized inverse propensity score weights were constructed using logistic regression to account for differential selection of alloHCT over chemotherapy. Weighted generalized linear models adjusted costs and utilization (hospitalizations, inp2017-01-01T00:00:00Z2017 Jun2025-04-19T22:41:07.452Z2019-03-26T23:38:51ZS-EPMC54973122826392010.1016/j.bbmt.2017.02.017